KAI Pharmaceuticals

KAI is a clinical-stage, biopharmaceutical company whose lead peptide product candidate, KAI-4169, is in development for the treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). CKD-MBD is characterized by an elevation of parathyroid hormone also referred to as secondary hyperparathyroidism. (SHPT).

Building on promising, early-stage clinical data, KAI has advanced KAI-4169 into Phase 2 clinical development in end-stage renal disease (ESRD) patients on dialysis, which is expected to complete in the second half of 2011. In addition, preclinical research is being conducted on pre-hemodialysis applications of KAI-4169.

KAI’s leadership team has a strong background and track record in successful product development and commercialization. The Company is backed by a leading syndicate of venture investors, having raised a combined total of $63 million in Series A and B rounds. KAI is headquartered in South San Francisco, California.

Recent Highlights

KAI recently completed enrollment in a Phase 2 multiple ascending dose study of KAI-4169. The Phase 2 trial was designed to assess the safety, tolerability and efficacy of thrice weekly intravenous (IV) doses of KAI-4169 administered during hemodialysis in patients with SHPT. Previous Phase 1 data demonstrated that single IV doses of KAI-4169 were safe and well-tolerated and resulted in sustained reductions in serum levels of parathyroid hormone in both healthy volunteers and ESRD patients with SHPT.